Literature DB >> 8263115

Establishment and characterisation of murine cells constitutively expressing the fusion, nucleoprotein and matrix proteins of measles virus.

P Beauverger1, R Buckland, F Wild.   

Abstract

To advance our understanding of the immunobiology of measles virus (MV) infections, we have investigated the possibility of establishing cell lines constitutively expressing the individual MV antigens. In contrast to previously published studies, we show that it is possible to establish cell lines expressing high levels of fusion (F), nucleoprotein (NP) and matrix (M) MV proteins. Once cloned, the cell lines were stable with high levels of expression for more than six months. The size and cell distribution of the NP and F proteins were similar to those observed in MV- or vaccinia-MV recombinant-infected cells. In contrast, the distribution of the M protein, although being similar to that of MV-infected cells, differed from that of Vaccinia-M recombinant virus-infected cells. Preliminary results suggest that these cell lines will be useful tools for studying the contribution of individual MV antigens to the cell-mediated immune response to this virus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8263115     DOI: 10.1016/0166-0934(93)90055-v

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  8 in total

1.  Proteolytic cleavage of the fusion protein but not membrane fusion is required for measles virus-induced immunosuppression in vitro.

Authors:  A Weidmann; A Maisner; W Garten; M Seufert; V ter Meulen; S Schneider-Schaulies
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Association of persistent wild-type measles virus RNA with long-term humoral immunity in rhesus macaques.

Authors:  Ashley N Nelson; Wen-Hsuan W Lin; Rupak Shivakoti; Nicole E Putnam; Lisa Mangus; Robert J Adams; Debra Hauer; Victoria K Baxter; Diane E Griffin
Journal:  JCI Insight       Date:  2020-02-13

3.  A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles.

Authors:  Chien-Hsiung Pan; Catherine E Greer; Debra Hauer; Harold S Legg; Eun-Young Lee; M Jeff Bergen; Brandyn Lau; Robert J Adams; John M Polo; Diane E Griffin
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

4.  Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice.

Authors:  M Jeff Bergen; Chien-Hsiung Pan; Catherine E Greer; Harold S Legg; John M Polo; Diane E Griffin
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

5.  HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection.

Authors:  Nitya Nair; William J Moss; Susana Scott; Nanthalile Mugala; Zaza M Ndhlovu; Kareem Lilo; Judith J Ryon; Mwaka Monze; Thomas C Quinn; Simon Cousens; Felicity Cutts; Diane E Griffin
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

6.  A durable protective immune response to wild-type measles virus infection of macaques is due to viral replication and spread in lymphoid tissues.

Authors:  Wen-Hsuan W Lin; Eileen Moran; Robert J Adams; Robert E Sievers; Debra Hauer; Steven Godin; Diane E Griffin
Journal:  Sci Transl Med       Date:  2020-04-01       Impact factor: 17.956

7.  Interplay between virus-specific effector response and Foxp3 regulatory T cells in measles virus immunopathogenesis.

Authors:  Caroline I Sellin; Jean-François Jégou; Joëlle Renneson; Johan Druelle; T Fabian Wild; Julien C Marie; Branka Horvat
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240

8.  Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA.

Authors:  Wen-Hsuan W Lin; Chien-Hsiung Pan; Robert J Adams; Beth L Laube; Diane E Griffin
Journal:  mBio       Date:  2014-04-15       Impact factor: 7.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.